{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02886884",
      "OrgStudyIdInfo": {
        "OrgStudyId": "20160686"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "1R01HL134558-01",
            "SecondaryIdType": "U.S. NIH Grant/Contract",
            "SecondaryIdLink": "https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=1R01HL134558-01&Fy=all"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "University of Miami",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects",
      "OfficialTitle": "A Phase I/II, Randomized, Double Blind, Pilot Trial to Evaluate the Safety and Efficacy of Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects",
      "Acronym": "ACESO"
    },
    "StatusModule": {
      "StatusVerifiedDate": "January 2021",
      "OverallStatus": "Active, not recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "October 20, 2017",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "September 2023",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "September 2024",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "August 29, 2016",
      "StudyFirstSubmitQCDate": "August 31, 2016",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "September 1, 2016",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "January 28, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "February 2, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor-Investigator",
        "ResponsiblePartyInvestigatorFullName": "Joshua M Hare",
        "ResponsiblePartyInvestigatorTitle": "Sponsor - Investigator",
        "ResponsiblePartyInvestigatorAffiliation": "University of Miami"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Joshua M Hare",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "National Heart, Lung, and Blood Institute (NHLBI)",
            "CollaboratorClass": "NIH"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "Yes",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "This is a 16 subject trial to demonstrate the safety of allogeneic hMSCs administered via infusion therapy for diabetic subjects with endothelial dysfunction."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Diabetes Mellitus"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Diabetes",
          "Endothelial dysfunction",
          "Stem cells"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "10",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "20 million allogeneic hMSCs",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Eight (8) subjects will be delivered via peripheral intravenous infusion of 20 million allogeneic Mesenchymal Human Stem Cells (hMSCs)",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: 20 million Allogeneic Mesenchymal Human Stem Cells"
              ]
            }
          },
          {
            "ArmGroupLabel": "100 million hMSCs",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Eight (8) subjects will be delivered via peripheral intravenous infusion of 100 million allogeneic Mesenchymal Human Stem Cells (hMSCs)",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: 100 million Allogeneic Mesenchymal Human Stem Cells"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "20 million Allogeneic Mesenchymal Human Stem Cells",
            "InterventionDescription": "1 single intravenous infusion",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "20 million allogeneic hMSCs"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "allo-hMSCs",
                "stem cells"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "100 million Allogeneic Mesenchymal Human Stem Cells",
            "InterventionDescription": "1 single intravenous infusion",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "100 million hMSCs"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "allo-hMSCs",
                "stem cells"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Incidence of Treatment Related Serious Adverse Events (TE-SAEs)",
            "PrimaryOutcomeDescription": "TE-SAEs are defined as the composite of: death, non-fatal pulmonary embolism, stroke, hospitalization for worsening dyspnea and clinically significant laboratory test abnormalities. TE-SAEs will be assessed by treating physician",
            "PrimaryOutcomeTimeFrame": "Up to one month (post infusion)"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "EPC-CFU levels",
            "SecondaryOutcomeDescription": "Endothelial Progenitor Cell Colony Forming Units (EPC-CFU) will be assessed from blood samples",
            "SecondaryOutcomeTimeFrame": "Up to 12 months (post infusion)"
          },
          {
            "SecondaryOutcomeMeasure": "CRP Marker Levels",
            "SecondaryOutcomeDescription": "C-Reactive Protein (CRP) levels will be assessed from blood samples and reported in mg/L",
            "SecondaryOutcomeTimeFrame": "Up to 12 months (post infusion)"
          },
          {
            "SecondaryOutcomeMeasure": "Circulating Angiogenic Factor Levels",
            "SecondaryOutcomeDescription": "Circulating Angiogenic Factor levels including Vascular Endothelial Growth Factor (VEGF), Stem Cell Factor (SCF) and Stromal Cell-Derived Factor 1 (SDF-1) will be assessed from blood samples and reported in ng/mL",
            "SecondaryOutcomeTimeFrame": "Up to 12 months (post infusion)"
          },
          {
            "SecondaryOutcomeMeasure": "Flow Mediated Diameter Percentage (FMD%)",
            "SecondaryOutcomeDescription": "FMD will be assessed using brachial artery ultrasound",
            "SecondaryOutcomeTimeFrame": "Up to 12 months (post infusion)"
          },
          {
            "SecondaryOutcomeMeasure": "Circulating Inflammatory Marker Levels",
            "SecondaryOutcomeDescription": "Circulating inflammatory marker levels including Interleukin (IL) -1, IL-6 and Tumor Necrosis Factor (TNF) Alpha will be assessed from blood samples and reported in pg/mL",
            "SecondaryOutcomeTimeFrame": "Up to 12 months (post infusion)"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nBe ≥ 21 and < 90 (inclusive) years of age.\nProvide written informed consent.\nHave endothelial dysfunction defined by impaired flow-mediated vasodilation (FMD <7%).\nHave an ejection fraction > 45% by gated blood pool scan, two- dimensional echocardiogram, cardiac MRI, cardiac CT or left ventriculogram within the prior 3 months.\nHave Diabetes mellitus type 2 documented by hemoglobin adult type 1 component (A1C) > 7% or on medical therapy for diabetes.\nFemales of childbearing potential must use two forms of birth control for the duration of the study. Female subjects must undergo a blood or urine pregnancy test at screening and within 36 hours prior to infusion.\n\nExclusion Criteria:\n\nIn order to participate in this study, a subject Must Not:\n\nBe younger than 21 years or older than 90 years of age.\nHave a baseline glomerular filtration rate <35 ml/min 1.73m^2 estimated using the Modification of Diet in renal disease (MDRD) formula.\nHave an ejection fraction <45% by gated blood pool scan, two-dimensional echocardiogram, cardiac MRI, cardiac CT or left ventriculogram within the past year, as documented by medical history.\nHave poorly controlled blood glucose levels with hemoglobin A1C > 8.5%.\nHave a history of proliferative retinopathy or severe neuropathy requiring medical treatment.\nHave a hematologic abnormality as evidenced by hematocrit < 25%, white blood cell < 2,500/ul or platelet values < 100,000/ul without another explanation.\nHave liver dysfunction, as evidenced by enzymes (AST and ALT) greater than three times the upper limit of normal.\nHave a bleeding diathesis or coagulopathy (INR > 1.3), cannot be withdrawn from anticoagulation therapy, or will refuse blood transfusions.\nHave Lymphadenectomy or Lymph node dissection in the right arm.\nBe an organ transplant recipient or have a history of organ or cell transplant rejection.\nHave a clinical history of malignancy within the past 5 years (i.e., subjects with prior malignancy must be disease free for 5 years), except curatively- treated basal cell or squamous cell carcinoma, or cervical carcinoma.\nHave a condition that limits lifespan to < 1 year.\nHave a history of drug or alcohol abuse within the past 24 months.\nBe on chronic therapy with immunosuppressant medication, such as corticosteroids or Tumor Necrosis Factor - alpha (TNFα) antagonists.\nBe serum positive for HIV, Syphilis - VDRL (Confirmation with FTA-ABS if needed (Syphilis)), hepatitis B surface antigen or viremic hepatitis C.\nBe currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial.\nBe pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods.\nAny other condition that in the judgment of the Investigator would be a contraindication to enrollment or follow-up.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "21 Years",
      "MaximumAge": "90 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Joshua M Hare, MD",
            "OverallOfficialAffiliation": "ISCI / University of Miami Miller School of Medicine",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "University of Miami Miller School of Medicine",
            "LocationCity": "Miami",
            "LocationState": "Florida",
            "LocationZip": "33136",
            "LocationCountry": "United States"
          }
        ]
      }
    },
    "ReferencesModule": {
      "SeeAlsoLinkList": {
        "SeeAlsoLink": [
          {
            "SeeAlsoLinkLabel": "Interdisciplinary stem cell institute at the University of Miami website",
            "SeeAlsoLinkURL": "http://isci.med.miami.edu"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M6267",
            "ConditionBrowseLeafName": "Diabetes Mellitus",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC18",
            "ConditionBrowseBranchName": "Nutritional and Metabolic Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC19",
            "ConditionBrowseBranchName": "Gland and Hormone Related Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    }
  }
}